EUVIMEDEUVIMED entdecken
Multizentrische Studie

Multicentre investigation of Wickerhamomyces anomalus fungemia in India: emerging resistance and mechanistic insights

Shristi Verma, Ragini Tilak, Gagandeep Singh iD, Shreya Singh, Anjna Kumari, Shivaprakash M Rudramurthy iD, Bram Spruijtenburg, Jacques F Meis, Theun de Groot, Eelco F J Meijer, Munesh K Gupta, Immaculata Xess und 2 weitere

Journal of Antimicrobial Chemotherapy · 2026

DOI: 10.1093/jac/dkaf420 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Shristi Verma und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Hauptthemen laut MEDLINE: Antifungal Agents, Drug Resistance, Fungal, Saccharomycetales, Fungemia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: Indian Council of Medical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Wickerhamomyces anomalus is an emerging pathogen in Indian hospitals, with limited data on antifungal resistance and its clinical impact. We aimed to explore its antifungal susceptibility, clinical outcomes, resistance mechanisms and molecular epidemiology. Materials and methods Seventy clinical isolates of W. anomalus (2016–24) were collected from PGIMER, Chandigarh (n = 29), BHU, Varanasi (n = 33), and AIIMS, New Delhi (n = 8). Antifungal susceptibility testing (AFST) was done for amphotericin B, fluconazole, voriconazole, itraconazole, posaconazole, caspofungin, anidulafungin and micafungin. ERG11 sequencing, ERG11, MDR1 and CDR1 expression analysis (RT-qPCR), biofilm formation, ergosterol content and genetic relatedness [short tandem repeat (STR) typing] were performed.

Results

The AFST (n = 70) showed that 72% isolates were non-wild-type (NWT) for fluconazole, 17% cross-resistance with voriconazole, and 1.4% with micafungin. Among fungemia cases, 53.2% occurred in neonates. Respiratory distress syndrome was the most common associated comorbidity, 26/62 (41.9%), with mortality in 31/62 (50%). ERG11 sequencing revealed four non-synonymous mutations, N41K, R420K, P485L, and T486K(novel), in 28 (55%) NWT isolates. Gene expression analysis revealed upregulation of ERG11 (12.72-fold) and CDR1 (3.08-fold) in NWT isolates without ERG11 mutations. Biofilm formation was higher in NWT versus wild-type. STR genotyping revealed 22 genotypes and 5 clusters (≥3 isolates), suggesting clonal transmission.

Conclusion

This multicentre study demonstrates the emergence of fluconazole-NWT W. anomalus in Indian hospitals, predominantly affecting neonates, with a high mortality. Resistance was associated with ERG11 mutations, efflux pump overexpression and biofilm formation. These findings highlight that the drug-resistant W. anomalus fungemia is an emerging concern.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsDrug Resistance, FungalSaccharomycetalesFungemiaHumansIndiaMicrobial Sensitivity TestsMaleFemaleAdultMiddle AgedYoung AdultInfant, NewbornInfantChild, PreschoolChildAdolescentBiofilmsMolecular EpidemiologyAgedErgosterolGenotype

Substanzen

Antifungal AgentsErgosterol

Autor:innen und Institutionen

  • Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Department of Microbiology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
  • Department of Microbiology, All India Institute of Medical Sciences, New Delhi, India.
  • Department of Medical Parasitology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Department of Medical Microbiology, Radboudumc-CWZ Center of Expertise for Mycology, Nijmegen, The Netherlands.
  • Department of Medical Microbiology and Immunology, Canisius-Wilhelmina Hospital (CWZ)/Dicoon, Nijmegen, The Netherlands.

ORCID-Profile: Gagandeep Singh, Shivaprakash M Rudramurthy, Harsimran Kaur, Anup Ghosh

Förderung

  • Indian Council of Medical Research

Zitieren

APA

Verma, S., Tilak, R., Singh, G., Singh, S., Kumari, A., Rudramurthy, S. M., Spruijtenburg, B., Meis, J. F., de Groot, T., Meijer, E. F. J., Gupta, M. K., Xess, I., Kaur, H., & Ghosh, A. (2026). Multicentre investigation of Wickerhamomyces anomalus fungemia in India: emerging resistance and mechanistic insights. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf420

Vancouver

Verma S, Tilak R, Singh G, Singh S, Kumari A, Rudramurthy SM, et al. Multicentre investigation of Wickerhamomyces anomalus fungemia in India: emerging resistance and mechanistic insights. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkaf420

BibTeX
@article{Verma2026,
  author = {Verma, Shristi and Tilak, Ragini and Singh, Gagandeep and Singh, Shreya and Kumari, Anjna and Rudramurthy, Shivaprakash M and Spruijtenburg, Bram and Meis, Jacques F and de Groot, Theun and Meijer, Eelco F J and Gupta, Munesh K and Xess, Immaculata and Kaur, Harsimran and Ghosh, Anup},
  title = {Multicentre investigation of Wickerhamomyces anomalus fungemia in India: emerging resistance and mechanistic insights},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  doi = {10.1093/jac/dkaf420}
}
Kostenlos starten →